Molnupiravir has serious safety concern, says ICMR
Antiviral medicine molnupiravir which recently got approval from the CDSCO in India and is being manufactured by many pharma companies, has serious safety concerns, and thus has not been included in the national COVID-19 clinical protocol recommended by the health ministry, the Indian Council of Medical Research (ICMR) director general Balram Bhargava said.
Bhargava said the COVID-19 task force has debated twice whether to include the Molnupiravir in the COVID-19 treatment protocol but decided against it because of concerns.